Clinical Trial Update: Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients [Phase 4]

View source ↗

Summary

Phase 4 trial updating pharmacokinetics and safety of Endari (L-glutamine) in sickle cell disease patients completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• ENDARI (GLUTAMINE)

Snippet

Sponsor: Emmaus Medical, Inc. | Conditions: Sickle Cell Disease, Pharmacokinetics | Phase 4 | Status: COMPLETED